At a Glance
- Companies: AGC Biologics (AGC Inc. subsidiary)
- Locations: Yokohama Technical Center, Tsurumi-ku, Yokohama, Japan
- Deal value: JPY 50bn (~US$350m); 20,000m² facility; 400 jobs
- Focus area: Mammalian cell culture, mRNA, cell therapy (preclinical to commercial)
- Next steps: Operational 2026 (cell therapy/mRNA); full 2027
What happened?
AGC Biologics announced plans for a new manufacturing facility at its Yokohama Technical Center in Japan, part of a strategic growth initiative to expand high‑quality biopharma services in Asia. The 20,000m² four‑storey site will offer preclinical through commercial services for mammalian protein biologics, cell therapies and mRNA, featuring multiple 2,000L single‑use bioreactors and larger 4,000L+ reactors—one of Japan’s largest mammalian capacities.
Why does it matter?
The facility addresses surging regional demand for biologics and ATMPs, complementing AGC’s Chiba site (mammalian/microbial) and global network. Dual‑use vaccine capabilities enhance pandemic preparedness, supported by METI grant.
Who’s behind it?
AGC Biologics, with sites in US/Europe/Japan, leverages Yokohama’s strategic location for APAC innovators. CEO Patricio Massera emphasised regional expertise and flexibility.
How was it achieved?
Funded by JPY 50bn investment and METI grant, the site integrates cell therapy (2025 PD start), mRNA/mammalian (2026) and full operations (2027).
What’s next?
Cell therapy PD launches 2025; manufacturing ramps 2026–2027, employing 400 and strengthening AGC’s global CDMO leadership.
What are people saying?
Patricio Massera: “Meet global demand… scientific expertise, technical flexibility.”